OLBA HEALTHCARE HOLDINGS, Inc. (2689.T)
Okayama, JP
OLBA HEALTHCARE HOLDINGS, Inc., founded in 1921 and based in Okayama, Japan, provides an extensive range of healthcare and life science solutions to a diverse clientele across the country. Its customers include medical facilities, academic institutions, corporate research laboratories, individuals, and elderly care providers. The company's operations span several key areas. Its Medical Equipment business acts as a wholesale distributor for a wide array of advanced medical devices. This includes prosthetic and implantable items such as artificial joints, pacemakers, and coronary stents; surgical tools like steel instruments and ultrasonic scalpels; and diagnostic imaging systems such, as MRI and CT scanners. Additionally, they supply essential hospital equipment, including respirators, intraoperative monitors, and surgical lighting. In the realm of life sciences, OLBA HEALTHCARE offers specialized reagents and apparatus for genetic research, cell culture, and protein analysis. They also provide automated analyzers for biochemistry, immunology, and blood diagnostics, along with various testing reagents. Furthermore, the company performs dedicated DNA analysis services. The Supply Processing and Distribution (SPD) business supports clients by managing inventory, information, and procurement functions efficiently. Finally, the Nursing Care Products business focuses on enhancing the well-being of those requiring care. This segment offers rental services for nursing care equipment and sells welfare aids such as portable toilets and bathing solutions. They are also involved in managing a program designed to facilitate comfortable long-term care at home, referred to as "long-term care reform." The company rebranded from Kawanishi Holdings, Inc. to OLBA HEALTHCARE HOLDINGS, Inc. in January 2021.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.29% | -0.52% | -1.14% | -1.28% | +4.04% | +1.21% | -2.48% | +14.91% | +24.66% | +74.00% | +390.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+3.5% Q1'26: +4.6% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-4.1% Q1'26: +48.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.6% Q1'26: +1.7% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+12.4% ★ Q1'26: +11.1% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-0.6% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×1.14× ★ Q1'26: 1.50× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 17.1K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Katsuyuki Kuwamura | MD, GM of Sales Headquarters & Director | — | male |
| Kyousuke Isoda | Senior MD, Head of Corporate Planning Headquarters & Director | — | male |
| Midori Matsui | Internal Audit Office Manager | — | — |
| Nobuharu Murata | MD, GM of Administration & Director | — | male |
| Yohei Maeshima | Chairman, President & Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2689.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
